Compugen

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Compugen reports Q1 loss, showcases promising cancer immunotherapy approach

Compugen's Q1 2023 performance reflects a strategic focus on capital efficiency and milestone achievement.
Their innovative triple combination approach in cancer immunotherapy shows promise, with encouraging clinical benefits observed.
While managing R&D expenses and translating clinical benefits into marketable products are challenges, opportunities exist in disciplined cash deployment and exploration of biomarkers.
Overall, Compugen's financial discipline, promising clinical data, and strategic focus position them well for future growth in the oncology space.

Compugen (CGEN) reports positive ASCO results and solid financial standing

Compugen (CGEN) showcases promising results in cancer immunotherapy combinations, maintaining a strong financial position despite increased R&D expenses. The company's differentiated approach and focus on milestone achievement through 2024 position it well for future growth, although challenges in enrollment delays and managing expenses persist.

Compugen reports Q3 progress with promising clinical data and partnerships

Compugen's Q3 2023 performance reflects progress in clinical trials and financial stability with a cash balance of $57.5 million.
Strengths lie in innovative drug discovery approaches, successful clinical outcomes, and strategic partnerships.
Challenges include competitive enrollment landscape, cost management, and market acceptance of novel treatments.
Opportunities exist in upcoming data reporting, novel drug targets, and collaborations for future growth and success.

Compugen reports robust earnings and strategic partnerships drive growth

Compugen's Q4 2023 performance reflects strong financial results and notable achievements in clinical advancements and partnerships.
The company's financial stability, strategic focus, and robust pipeline position them well for future growth and innovation.
While facing challenges in clinical trial outcomes and partnership strategies, Compugen has opportunities to drive further growth through data insights and collaborations.

Compugen reports solid Q1 performance, poised for growth in 2024

Compugen's Q1 2024 performance reflects financial stability, operational efficiency, and progress in advancing key drug candidates towards clinical trials, underpinned by a robust AI discovery platform and strategic partnerships.
While challenges like ongoing R&D investments and achieving profitability persist, opportunities in milestone achievements, data readouts, and strategic collaborations position Compugen for future growth and value creation.
Navigating the biopharmaceutical landscape with innovation, financial discipline, and strategic foresight, Compugen stands poised to capitalize on market opportunities, drive pipeline progression, and enhance shareholder value.

Compugen reports Q2 revenue of $6.7M, highlights innovative drug strategies

Compugen's Q2 2024 performance reflects steady revenue generation and prudent financial management. The company's strengths in innovative drug development and strategic collaborations present promising growth opportunities. Addressing challenges in clinical evidence and cash burn will be crucial for sustained success.

Compugen reports solid Q3 earnings, advances promising ovarian cancer therapies

Compugen's strong financial position, promising clinical data on multiple therapies, and strategic focus on ovarian cancer treatment advancements position the company for potential growth. Challenges lie in maintaining treatment efficacy and navigating regulatory discussions for future developments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2020 Results - Earnings Call Transcript

Compugen Ltd (NASDAQ: CGEN) reports updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and a dose-escalation combination study with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab). COM701 is an antibody targeting PVRIG, a novel immune checkpoint.

Compugen's COM701 Shows Ongoing Durable Signals In Early-Stage Solid Tumor Studies

HOLON, Israel, Feb. 25, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the fourth quarter and full year ended December 31, 2020. "Our encouraging new data...

Compugen Reports Fourth Quarter and Full Year 2020 Results

Compugen Ltd (NASDAQ: CGEN) expands its clinical collaboration agreement with Bristol-Myers Squibb Co (NYSE: BMY), wherein Bristol Myers will supply Opdivo (nivolumab) for Compugen's Phase 1b cohort expansion study evaluating COM701, anti-PVRIG antibody. The study will assess COM701 combined with Opdivo in selected cancer indications, expected to start in the second quarter of 2021.

Compugen To Test COM701, Opdivo Combination In Solid Tumor Settings

AstraZeneca

HOLON, Israel, Dec. 23, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today progress from its ongoing license agreement with AstraZeneca (LSE: AZN) (STO: AZN) (NASDAQ: AZN) under...

Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2020 Results - Earnings Call Transcript

HOLON, Israel, Sept. 30, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the addition of Nils Lonberg, Ph.D., to its Scientific Advisory Board (SAB). Dr. Lonberg is a pioneer in...

Compugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientific Advisory Board

HOLON, Israel, Sept. 8, 2020 /PRNewswire/ -- Compugen Ltd.

Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody

HOLON, Israel, Sept. 3, 2020 /PRNewswire/ -- Compugen Ltd.

Compugen to Present at Upcoming September 2020 Investor Conferences

HOLON, Israel, Aug. 28, 2020 /PRNewswire/ -- Compugen Ltd.

Compugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent

Compugen Ltd (CGEN) CEO Anat Dayag on Q2 2020 Results - Earnings Call Transcript

HOLON, Israel, July 30, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the second quarter ended June 30, 2020.

Compugen Reports Second Quarter 2020 Results

Compugen: Clinical Data Supports COM701 As A Potential Breakthrough Cancer Treatment

HOLON, Israel, July 16, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its second quarter 2020 financial results on Thursday, July 30, 2020 before.

Compugen to Release Second Quarter 2020 Results on Thursday, July 30, 2020

Compugen's Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma

HOLON, Israel, June 1, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration has cleared the investigational new drug (IND) application for...

Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor

Roche Holding AG

Vertex Pharmaceuticals

Here are the hottest companies coming up in the biotech sector next month.

2 Top Biotech Picks for May

Investors need to pay close attention to Compugen (CGEN) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Compugen (CGEN) Stock?

Compugen (CGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Compugen (CGEN) Stock Stands Out in a Strong Industry

Roche's Upcoming Phase 2 TIGIT Results At ASCO Could Read Through To Compugen's COM902 TIGIT Candidate

Chegg

GenMark Diagnostics

Top Ranked Momentum Stocks to Buy for May 8th

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q1 2020 Results - Earnings Call Transcript

Its new discovery in the field of cancer immunotherapy produced mixed clinical results, but it certainly has ample backing from the big players.

Can This Biotech Shed New Light on Cancer Immunotherapies?

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

What Makes Compugen (CGEN) a New Strong Buy Stock

When the financial markets enter their once-a-decade crisis mode, it often feels impossible to think rationally and to make normal investing decisions.

News for Compugen Stock (CGEN)